A Phase 3 interventional study of RSVpreF and Placebo in RESPIRATORY SYNCYTIAL VIRUS (RSV), sponsored by Pfizer. Completed at 36 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-08.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to learn about the safety and immunogenicity of a study vaccine (called RSVpreF) in several adult groups. Respiratory Syncytial Virus (RSV) is a common type of virus (germ) that can cause severe illness, where medical help is needed. RSV can lead to airway diseases in all ages. Vaccines help your body make antibodies which help fight against diseases. This is called an immune response. This study will measure how much antibody participants make after receiving RSVpreF (immunogenicity).
The study consists of 2 groups (Substudy A and Substudy B).
Substudy A is seeking approximately 675 participants who are:
Participants will need to come to the study clinic at least 2 times. At the first clinic visit, participants will receive 1 shot of RSVpreF or placebo in the arm by chance. A placebo looks like the study vaccine but contains no active ingredients. At each clinic visit, a blood sample will be taken. A third (final) visit can be either completed in clinic or via telephone contact. This study is about 6 months long for each participant.
Substudy B is seeking approximately 200 participants who are:
This is a Phase 3 protocol that will assess the safety, tolerability, and immunogenicity of Pfizer's RSVpreF in adults at high risk of severe RSV disease. Each substudy design is detailed separately, and these substudies may be conducted in parallel, as required by the clinical plan, within the framework of this protocol.
Substudy A Design:
This is a Phase 3, multicenter, randomized, double-blinded, placebo-controlled study that will assess the safety, tolerability, and immunogenicity of Pfizer's RSVpreF in adults 18 to \<60 years of age considered to be at high risk of RSV disease due to certain chronic medical conditions.
Approximately 675 participants ≥18 to \<60 years of age considered at high risk of RSV disease due to certain chronic medical conditions, excluding immunocompromising conditions, will be randomized to receive a single 120-µg dose of RSVpreF or placebo in a 2:1 ratio. Enrollment will be monitored to help ensure distribution of vaccination across the age range. The duration of study participation for each participant will be 6 months, with 3 scheduled visits.
All participants will have blood drawn at baseline prior to vaccination and at 1 month after vaccination to assess immunogenicity. Immunogenicity elicited at 1 month after vaccination with RSVpreF in Substudy A will be bridged to the immunogenicity of participants 60 years of age and older in the C3671013 study, in which RSVpreF efficacy was demonstrated.
Local reaction and systemic event data will be collected in an e-diary for 7 days after study vaccination (Days 1 through 7, where Day 1 is the day of vaccination). Reported Grade 3 reactogenicity will be assessed by the study site to determine if an unscheduled visit is required.
For all participants, AEs will be collected from informed consent through 1 month following study intervention administration, and AESIs, NDCMCs and SAEs will be collected from informed consent throughout study participation. In addition, AEs occurring up to 48 hours after blood draws that are related to study procedures will be collected.
Substudy B Design:
This is a Phase 3, single-arm, open-label, multicenter study that will assess the safety, tolerability, and immunogenicity of Pfizer's RSVpreF in immunocompromised adults.
Substudy B included approximately 200 immunocompromised adults ≥18 years of age, that will receive 2 120-µg doses of RSVpreF with an interval of 1 month. Approximately 100 participants will be ≥60 years of age and approximately 100 participants will be ≥18 to 60 years of age. Enrollment will be monitored to help ensure distribution of vaccination across the age ranges and underlying immunocompromising conditions. The duration of study participation for each participant will be 7 months, with 4 scheduled visits. All participants will have blood drawn at baseline prior to vaccination and at 1 month after (each) vaccination to assess immunogenicity.
Local reaction and systemic event data will be collected in an e-diary for 7 days after study vaccination (Days 1 through 7, where Day 1 is the day of vaccination). Reported Grade 3 reactogenicity will be assessed by the study site to determine if an unscheduled visit is required.
For all participants, AEs will be collected from informed consent through 1 month following the last study intervention administration, and AESIs, NDCMCs and SAEs will be collected from informed consent throughout study participation. In addition, AEs occurring up to 48 hours after blood draws that are related to study procedures will be collected.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Substudy A Inclusion Criteria:
Participants who are considered at high risk of RSV disease by virtue of the following:
Chronic medical conditions for this substudy are defined as:
- Duration greater than 6 months.
Requires regular medical follow-up or ongoing medication or hospitalization in the previous year.
Substudy A Exclusion Criteria:
Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
Note: Specific criteria for participants with known stable infection with can be found in protocol.
Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, immunosuppressive monoclonal antibodies, systemic *, eg, for cancer or an disease, or radiotherapy, from 60 days before study intervention administration or planned receipt throughout the study.
*Applies to systemic corticosteroids administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent (eg, for cancer or an autoimmune disease). Systemic corticosteroids administered at a dose of \<20 mg/day of prednisone or equivalent are permitted. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin, eyes, or ears) corticosteroids are permitted.
Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration or planned receipt of these medications prior to the final blood draw.
Note: Monoclonal antibodies with targeted mechanisms of action used in the management of chronic illnesses (eg, migraine headaches, osteoporosis) are permitted, provided they do not meet exclusion criterion 7.
Substudy B Inclusion Criteria
Participants who are immunocompromised by virtue of the following:
•Having known advanced NSCLC with at least 1 of the following:
OR - Is currently undergoing maintenance hemodialysis treatment secondary to end-stage renal disease . OR - Is on active immunomodulator therapy (eg, TNFα inhibitor, tofacitinib, or MTX) for an autoimmune inflammatory disorder (eg, inflammatory arthritis, such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis, or inflammatory bowel disease, such as ulcerative colitis or Crohn's disease) at a stable*dose.
*Stable dose is defined as receiving the same dose for at least 3 months (84 days) with no changes in the 28 days prior to enrollment. See protocol for details on stable dose for MTX.
OR - Is receiving an SOT (kidney, liver, lung, or heart) at least 3 months (84 days) prior to enrollment (Visit 201) and with no acute rejection episodes within 2 months (60 days) prior to enrollment (Visit 201).
Substudy B Exclusion Criteria:
1.Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
2.History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.
3.Participants with a history of transplant rejection, or PTLD, or participants who have had treatment for these conditions within 3 months (84 days) prior to study enrollment.
4.Participants who do not have adequate deltoid muscle mass to allow intramuscular vaccination, in the opinion of the investigator.
5.Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
Note: Specific criteria for participants with known stable infection with HIV can be found in protocol.
6.Receipt of investigational or approved monoclonal antibodies against RSV within 6 months before study intervention administration.
7.Receipt of blood/plasma products or immunoglobulin (IVIG, SCIG) within 60 days before study intervention administration or planned receipt of these medications prior to the final blood draw.
Note: Please see the inclusion criteria in the protocol regarding criteria for targeted immunoglobulin therapies for underlying medical conditions.
Note: Monoclonal antibodies with targeted mechanisms of action used in the management of chronic illnesses (eg, migraine headaches, osteoporosis) are permitted.
8.Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation.
9.Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-month follow-up visit.
10.Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single 120-µg dose of RSVpreF at Visit 1
Biological: RSVpreF
Participants will receive placebo at Visit 1
Other: Placebo
Participants will receive 120-µg doses of RSVpreF at Visit 1 and Visit 2 (open label, single arm only)
Biological: RSVpreF
120-µg
Placebo
SSA: Percentage of Participants With Local Reactions Within 7 Days After Vaccination
Local reactions included pain at injection site, redness and swelling, recorded by participants in an electronic diary (e-diary). Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild: \>2.5 cm to 5.0 cm; moderate: \>5.0 cm to 10.0 cm; severe: \>10 cm.
Time frame: Within 7 Days after Vaccination (Vaccination on Day 1)
SSA: Percentage of Participants With Systemic Events Within 7 Days After Vaccination
Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C and severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.
Time frame: Within 7 Days after Vaccination (Vaccination on Day 1)
SSA: Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included. AEs included both serious and all non-serious adverse events.
Time frame: Within 1 Month after Vaccination (Vaccination on Day 1)
SSA: Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Throughout the Study
A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions.
Time frame: Within 6 Months after Vaccination (Vaccination on Day 1)
SSA: Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event were included in this outcome measure.
Time frame: Within 6 Months after Vaccination (Vaccination on Day 1)
SSA: Geometric Mean Ratio (GMR) Estimated by Ratio of the Geometric Mean Titers (GMTs) at 1 Month After Vaccination in Study C3671023 Participants Compared to Study C3671013 Adults >= 60 Years
In this outcome measure, GMTs for RSV A and RSV B neutralizing titers (NTs) are reported. In statistical section, GMT ratio estimated by the ratio of the GMTs for RSV A and RSV B serum NTs at 1 month after vaccination with RSVpreF in current study C3671023 participants to that in study C3671013 adults \>=60 years of age, is reported. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student t distribution).
Time frame: At 1 Month after Vaccination (Vaccination on Day 1)
SSA: Percentage of Participants With Seroresponse Rate and Difference in Seroresponse Rates of RSV A and RSV B Serum NTs at 1 Month After Vaccination for Participants in Study C3671023 and C3671013 Adults >= 60 Years
Seroresponse was defined as achieving a \>=4-fold rise from baseline (before vaccination), if the baseline measurement was above the lower limit of quantitation (LLOQ). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4\* LLOQ was considered a seroresponse.
Time frame: At 1 Month after Vaccination (Vaccination on Day 1)
SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1
Local reactions included pain at injection site, redness and swelling, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit=0.5 cm. Redness and swelling were graded as mild: \> 2.0 cm to 5.0 cm; moderate: \> 5.0 cm to 10.0 cm and severe: \> 10 cm.
Time frame: Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1)
SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2
Local reactions included pain at injection site, redness and swelling, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit = 0.5 cm. Redness and swelling were graded as mild: \>2.0 cm to 5.0 cm; moderate: \>5.0 cm to 10.0 cm and severe: \>10 cm.
Time frame: Within 7 Days after Vaccination 2 (Vaccination 2: 1-month post-vaccination 1 on Day 1)
SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1
Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C and severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.
Time frame: Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1)
SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2
Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C and severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.
Time frame: Within 7 Days after Vaccination 2 (Vaccination 2: 1-month post-vaccination 1 on Day 1)
SSB: Percentage of Participants With AEs From Vaccination 1 Through 1 Month After Vaccination 2
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included. AEs included both serious and all non-serious adverse events.
Time frame: From Vaccination 1 (on Day 1) through 1 month after Vaccination 2 (1 month after Vaccination 1) [approximately up to maximum of 2 months]
SSB: Percentage of Participants With NDCMCs From Vaccination Throughout the Study
A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions.
Time frame: From Vaccination 1 (on Day 1) through 6 months after Vaccination 2 (1 month after Vaccination 1) [approximately up to maximum of 7 months]
SSB: Percentage of Participants With SAEs Throughout the Study
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event were included in this outcome measure.
Time frame: From Vaccination 1 (on Day 1) through 6 months after Vaccination 2 (1 month after Vaccination 1) [approximately up to maximum of 7 months]
SSB: GMT of NT for RSV A and RSV B Before Vaccination 1
GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).
Time frame: Before Vaccination 1 (on Day 1)
SSB: GMT of NT for RSV A and RSV B 1 Month After Vaccination 1
GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).
Time frame: 1 Month After Vaccination 1 (on Day 1)
SSB: GMT of NT for RSV A and RSV B 1 Month After Vaccination 2
GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).
Time frame: 1 Month After Vaccination 2 (1-month post Vaccination 1)
SSB: Geometric Mean Fold Rise (GMFR) of NTs for RSV A and RSV B From Vaccination 1 to 1 Month Post-Vaccination 1
GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).
Time frame: At 1 Month After Vaccination 1 (on Day 1) to 1 Month Post-Vaccination 1
SSB: GMFR of NTs for RSV A and RSV B From Vaccination 1 to 1 Month Post-Vaccination 2
GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).
Time frame: At 1 Month After Vaccination 1 (on Day 1) to 1 Month Post-Vaccination 2
SSA: GMT of NTs for RSV A and RSV B Before Vaccination and 1 Month After Vaccination
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).
Time frame: SSA: Before Vaccination (on Day 1) and 1 Month After Vaccination
SSA: GMFR of NTs for RSV A and RSV B From Before Vaccination to 1 Month After Vaccination
GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).
Time frame: SSA: Before Vaccination (on Day 1) and 1 Month After Vaccination
Substudy A (SSA) and substudy B (SSB) are reported differently. SSA was randomized; SSB was open-label single-arm. Enrollment number 885 derived from participants with IP assigned in SSA (681 randomized) and SSB (204). Since no randomization in SSB (single arm), tables of SSB present 217 participants as starting substudy (signed informed consent), out of which 203 vaccinated. In SSA: 678 vaccinated.
| Milestone | SSA: RSVpreF | SSA: Placebo | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years |
|---|---|---|---|---|
| Started | 454 | 227 | 0 | 0 |
| Vaccinated | 453 | 225 | 0 | 0 |
| Completed | 432 | 218 | 0 | 0 |
| Not completed | 22 | 9 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 16 | 4 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 0 | 0 |
| Withdrew: Randomized but not vaccinated | 1 | 2 | 0 | 0 |
| Milestone | SSA: RSVpreF | SSA: Placebo | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years |
|---|---|---|---|---|
| Started | 0 | 0 | 101 | 116 |
| Vaccinated | 0 | 0 | 96 | 107 |
| Completed | 0 | 0 | 89 | 103 |
| Not completed | 0 | 0 | 12 | 13 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 4 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Withdrew: Enrolled but not vaccinated | 0 | 0 | 5 | 9 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
Local reactions included pain at injection site, redness and swelling, recorded by participants in an electronic diary (e-diary). Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild: \>2.5 cm to 5.0 cm; moderate: \>5.0 cm to 10.0 cm; severe: \>10 cm.
| Percentage of Participants | SSA: RSVpreF | SSA: Placebo |
|---|---|---|
| Pain at injection site: Mild | 29.7 (25.5 to 34.2) | 10.2 (6.6 to 14.9) |
| Pain at injection site: Moderate | 5.5 (3.6 to 8.1) | 0.4 (0.0 to 2.5) |
| Pain at injection site: Severe | 0 (0.0 to 0.8) | 0 (0.0 to 1.6) |
| Redness: Mild | 3.8 (2.2 to 6.0) | 0 (0.0 to 1.6) |
| Redness: Moderate | 2.2 (1.1 to 4.0) | 0.4 (0.0 to 2.5) |
| Redness: Severe | 0 (0.0 to 0.8) | 0 (0.0 to 1.6) |
| Swelling: Mild | 4.0 (2.4 to 6.2) | 0.4 (0.0 to 2.5) |
| Swelling: Moderate | 2.9 (1.5 to 4.9) | 0.4 (0.0 to 2.5) |
| Swelling: Severe | 0.2 (0.0 to 1.2) | 0 (0.0 to 1.6) |
Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C and severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.
| Percentage of participants | SSA: RSVpreF | SSA: Placebo |
|---|---|---|
| Fever: 38.0°C to 38.4°C | 0.4 (0.1 to 1.6) | 0.4 (0.0 to 2.5) |
| Fever: >38.4°C to 38.9°C | 1.1 (0.4 to 2.6) | 0.9 (0.1 to 3.2) |
| Fever: >38.9°C to 40.0°C | 0 (0.0 to 0.8) | 0 (0.0 to 1.6) |
| Fatigue: Mild | 18.2 (14.7 to 22.1) | 22.2 (17.0 to 28.2) |
| Fatigue: Moderate | 18.2 (14.7 to 22.1) | 15.6 (11.1 to 21.0) |
| Fatigue: Severe | 0.9 (0.2 to 2.3) | 0.4 (0.0 to 2.5) |
| Headache: Mild | 20.8 (17.2 to 24.9) | 18.7 (13.8 to 24.4) |
| Headache: Moderate | 7.3 (5.1 to 10.1) | 11.6 (7.7 to 16.5) |
| Headache: Severe | 0.2 (0.0 to 1.2) | 0 (0.0 to 1.6) |
| Muscle Pain: Mild | 15.7 (12.5 to 19.4) | 9.8 (6.2 to 14.4) |
| Muscle Pain: Moderate | 8.6 (6.2 to 11.6) | 6.2 (3.4 to 10.2) |
| Muscle Pain: Severe | 0 (0.0 to 0.8) | 0 (0.0 to 1.6) |
| Joint Pain: Mild | 7.1 (4.9 to 9.9) | 4.0 (1.8 to 7.5) |
| Joint Pain: Moderate | 5.1 (3.3 to 7.6) | 6.2 (3.4 to 10.2) |
| Joint Pain: Severe | 0.2 (0.0 to 1.2) | 0 (0.0 to 1.6) |
| Nausea: Mild | 9.3 (6.8 to 12.4) | 8.9 (5.5 to 13.4) |
| Nausea: Moderate | 2.4 (1.2 to 4.3) | 0.9 (0.1 to 3.2) |
| Nausea: Severe | 0 (0.0 to 0.8) | 0.4 (0.0 to 2.5) |
| Vomiting: Mild | 1.6 (0.6 to 3.2) | 0.4 (0.0 to 2.5) |
| Vomiting: Moderate | 0.4 (0.1 to 1.6) | 0.9 (0.1 to 3.2) |
| Vomiting: Severe | 0 (0.0 to 0.8) | 0 (0.0 to 1.6) |
| Diarrhea: Mild | 11.1 (8.3 to 14.4) | 12.4 (8.4 to 17.5) |
| Diarrhea: Moderate | 3.1 (1.7 to 5.2) | 3.6 (1.5 to 6.9) |
| Diarrhea: Severe | 0.7 (0.1 to 1.9) | 0.9 (0.1 to 3.2) |
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included. AEs included both serious and all non-serious adverse events.
| Percentage of participants | SSA: RSVpreF | SSA: Placebo |
|---|---|---|
| SSA: Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination | 7.1 (4.9 to 9.8) | 7.6 (4.5 to 11.8) |
A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions.
| Percentage of participants | SSA: RSVpreF | SSA: Placebo |
|---|---|---|
| SSA: Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Throughout the Study | 0.7 (0.1 to 1.9) | 2.2 (0.7 to 5.1) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event were included in this outcome measure.
| Percentage of participants | SSA: RSVpreF | SSA: Placebo |
|---|---|---|
| SSA: Percentage of Participants With Serious Adverse Events (SAEs) Throughout the Study | 1.1 (0.4 to 2.6) | 3.1 (1.3 to 6.3) |
In this outcome measure, GMTs for RSV A and RSV B neutralizing titers (NTs) are reported. In statistical section, GMT ratio estimated by the ratio of the GMTs for RSV A and RSV B serum NTs at 1 month after vaccination with RSVpreF in current study C3671023 participants to that in study C3671013 adults \>=60 years of age, is reported. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student t distribution).
| Titer | C3671023 SSA: RSVpreF | C3671013: RSVpreF, >=60 Years |
|---|---|---|
| RSV A | 41097 (37986.1 to 44463.4) | 26225 (24143.1 to 28485.7) |
| RSV B | 37416 (34277.9 to 40842.0) | 24680 (22504.3 to 27065.4) |
Seroresponse was defined as achieving a \>=4-fold rise from baseline (before vaccination), if the baseline measurement was above the lower limit of quantitation (LLOQ). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4\* LLOQ was considered a seroresponse.
| Percentage of participants | C3671023 SSA: RSVpreF | C3671013: RSVpreF, >=60 Years |
|---|---|---|
| RSV A | 93.1 (90.3 to 95.3) | 88.0 (84.4 to 91.0) |
| RSV B | 93.4 (90.6 to 95.5) | 85.0 (81.2 to 88.4) |
Local reactions included pain at injection site, redness and swelling, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit=0.5 cm. Redness and swelling were graded as mild: \> 2.0 cm to 5.0 cm; moderate: \> 5.0 cm to 10.0 cm and severe: \> 10 cm.
| Percentage of participants | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years |
|---|---|---|
| Pain at injection site: Mild | 25.0 (16.7 to 34.9) | 16.8 (10.3 to 25.3) |
| Pain at injection site: Moderate | 1.0 (0.0 to 5.7) | 0 (0.0 to 3.4) |
| Pain at injection site: Severe | 0 (0.0 to 3.8) | 0 (0.0 to 3.4) |
| Redness: Mild | 5.2 (1.7 to 11.7) | 1.9 (0.2 to 6.6) |
| Redness: Moderate | 1.0 (0.0 to 5.7) | 1.9 (0.2 to 6.6) |
| Redness: Severe | 0 (0.0 to 3.8) | 0 (0.0 to 3.4) |
| Swelling: Mild | 6.3 (2.3 to 13.1) | 0.9 (0.0 to 5.1) |
| Swelling: Moderate | 2.1 (0.3 to 7.3) | 1.9 (0.2 to 6.6) |
| Swelling: Severe | 0 (0.0 to 3.8) | 0 (0.0 to 3.4) |
Local reactions included pain at injection site, redness and swelling, recorded by participants in an e-diary. Pain at injection site was graded as mild: did not interfere with activity; moderate: interfered with activity and severe: prevented daily activity. Redness and swelling were measured and recorded in measuring device units, where 1 measuring device unit = 0.5 cm. Redness and swelling were graded as mild: \>2.0 cm to 5.0 cm; moderate: \>5.0 cm to 10.0 cm and severe: \>10 cm.
| Percentage of participants | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years |
|---|---|---|
| Pain at injection site: Mild | 42.6 (32.4 to 53.2) | 29.5 (21.0 to 39.2) |
| Pain at injection site: Moderate | 4.3 (1.2 to 10.5) | 1.9 (0.2 to 6.7) |
| Pain at injection site: Severe | 0 (0.0 to 3.8) | 0 (0.0 to 3.5) |
| Redness: Mild | 2.1 (0.3 to 7.5) | 1.9 (0.2 to 6.7) |
| Redness: Moderate | 0 (0.0 to 3.8) | 1.9 (0.2 to 6.7) |
| Redness: Severe | 0 (0.0 to 3.8) | 0 (0.0 to 3.5) |
| Swelling: Mild | 2.1 (0.3 to 7.5) | 3.8 (1.0 to 9.5) |
| Swelling: Moderate | 1.1 (0.0 to 5.8) | 5.7 (2.1 to 12.0) |
| Swelling: Severe | 0 (0.0 to 3.8) | 0 (0.0 to 3.5) |
Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C and severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.
| Percentage of participants | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years |
|---|---|---|
| Fever: 38.0°C to 38.4°C | 1.0 (0.0 to 5.7) | 0.9 (0.0 to 5.1) |
| Fever: >38.4°C to 38.9°C | 0 (0.0 to 3.8) | 0 (0.0 to 3.4) |
| Fever: >38.9°C to 40.0°C | 0 (0.0 to 3.8) | 0 (0.0 to 3.4) |
| Fatigue: Mild | 20.8 (13.2 to 30.3) | 19.6 (12.6 to 28.4) |
| Fatigue: Moderate | 16.7 (9.8 to 25.6) | 22.4 (14.9 to 31.5) |
| Fatigue: Severe | 2.1 (0.3 to 7.3) | 2.8 (0.6 to 8.0) |
| Headache: Mild | 29.2 (20.3 to 39.3) | 15.0 (8.8 to 23.1) |
| Headache: Moderate | 9.4 (4.4 to 17.1) | 6.5 (2.7 to 13.0) |
| Headache: Severe | 0 (0.0 to 3.8) | 0.9 (0.0 to 5.1) |
| Vomiting: Mild | 4.2 (1.1 to 10.3) | 0.9 (0.0 to 5.1) |
| Vomiting: Moderate | 0 (0.0 to 3.8) | 0 (0.0 to 3.4) |
| Vomiting: Severe | 0 (0.0 to 3.8) | 0 (0.0 to 3.4) |
| Nausea: Mild | 9.4 (4.4 to 17.1) | 3.7 (1.0 to 9.3) |
| Nausea: Moderate | 3.1 (0.6 to 8.9) | 4.7 (1.5 to 10.6) |
| Nausea: Severe | 0 (0.0 to 3.8) | 0 (0.0 to 3.4) |
| Diarrhea: Mild | 15.6 (9.0 to 24.5) | 12.1 (6.6 to 19.9) |
| Diarrhea: Moderate | 6.3 (2.3 to 13.1) | 5.6 (2.1 to 11.8) |
| Diarrhea: Severe | 0 (0.0 to 3.8) | 0 (0.0 to 3.4) |
| Muscle Pain: Mild | 18.8 (11.5 to 28.0) | 13.1 (7.3 to 21.0) |
| Muscle Pain: Moderate | 7.3 (3.0 to 14.4) | 5.6 (2.1 to 11.8) |
| Muscle Pain: Severe | 0 (0.0 to 3.8) | 1.9 (0.2 to 6.6) |
| Joint Pain: Mild | 10.4 (5.1 to 18.3) | 11.2 (5.9 to 18.8) |
| Joint Pain: Moderate | 7.3 (3.0 to 14.4) | 8.4 (3.9 to 15.4) |
| Joint Pain: Severe | 0 (0.0 to 3.8) | 1.9 (0.2 to 6.6) |
Systemic events included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain and joint pain. These were recorded by participants in an e-diary. Fever defined as oral temperature \>=38.0 degrees Celsius (deg C) and categorized as mild: \>=38.0 to 38.4 deg C, moderate: \>38.4 to 38.9 deg C and severe: \>38.9 to 40.0 deg C. Vomiting categorized as mild: 1-2 times in 24 hours (h); moderate: \>2 times in 24h; severe: required intravenous (IV) hydration. Diarrhea categorized as mild: 2-3 loose stools in 24h; moderate: 4-5 loose stools in 24h; severe: 6 or more loose stools in 24h. Headache, fatigue, nausea, muscle pain and joint pain were categorized as mild: didn't interfere with activity; moderate: some interference with activity; severe: prevented daily routine activity.
| Percentage of participants | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years |
|---|---|---|
| Fever: 38.0°C to 38.4°C | 0 (0.0 to 3.8) | 0 (0.0 to 3.5) |
| Fever: >38.4°C to 38.9°C | 0 (0.0 to 3.8) | 0 (0.0 to 3.5) |
| Fever: >38.9°C to 40.0°C | 0 (0.0 to 3.8) | 0 (0.0 to 3.5) |
| Fatigue: Mild | 19.1 (11.8 to 28.6) | 23.8 (16.0 to 33.1) |
| Fatigue: Moderate | 18.1 (10.9 to 27.4) | 19.0 (12.0 to 27.9) |
| Fatigue: Severe | 0 (0.0 to 3.8) | 0 (0.0 to 3.5) |
| Headache: Mild | 13.8 (7.6 to 22.5) | 19.0 (12.0 to 27.9) |
| Headache: Moderate | 10.6 (5.2 to 18.7) | 5.7 (2.1 to 12.0) |
| Headache: Severe | 0 (0.0 to 3.8) | 1.0 (0.0 to 5.2) |
| Vomiting: Mild | 2.1 (0.3 to 7.5) | 1.0 (0.0 to 5.2) |
| Vomiting: Moderate | 0 (0.0 to 3.8) | 0 (0.0 to 3.5) |
| Vomiting: Severe | 0 (0.0 to 3.8) | 0 (0.0 to 3.5) |
| Nausea: Mild | 5.3 (1.7 to 12.0) | 5.7 (2.1 to 12.0) |
| Nausea: Moderate | 1.1 (0.0 to 5.8) | 1.0 (0.0 to 5.2) |
| Nausea: Severe | 0 (0.0 to 3.8) | 0 (0.0 to 3.5) |
| Diarrhea: Mild | 6.4 (2.4 to 13.4) | 10.5 (5.3 to 18.0) |
| Diarrhea: Moderate | 5.3 (1.7 to 12.0) | 2.9 (0.6 to 8.1) |
| Diarrhea: Severe | 0 (0.0 to 3.8) | 0 (0.0 to 3.5) |
| Muscle Pain: Mild | 16.0 (9.2 to 25.0) | 15.2 (9.0 to 23.6) |
| Muscle Pain: Moderate | 3.2 (0.7 to 9.0) | 8.6 (4.0 to 15.6) |
| Muscle Pain: Severe | 0 (0.0 to 3.8) | 0 (0.0 to 3.5) |
| Joint Pain: Mild | 8.5 (3.7 to 16.1) | 12.4 (6.8 to 20.2) |
| Joint Pain: Moderate | 3.2 (0.7 to 9.0) | 4.8 (1.6 to 10.8) |
| Joint Pain: Severe | 0 (0.0 to 3.8) | 0 (0.0 to 3.5) |
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included. AEs included both serious and all non-serious adverse events.
| Percentage of participants | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years |
|---|---|---|
| SSB: Percentage of Participants With AEs From Vaccination 1 Through 1 Month After Vaccination 2 | 13.5 (7.4 to 22.0) | 22.4 (14.9 to 31.5) |
A NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects. Newly diagnosed chronic medical condition did not include illnesses considered to be temporary conditions.
| Percentage of participants | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years |
|---|---|---|
| SSB: Percentage of Participants With NDCMCs From Vaccination Throughout the Study | 2.1 (0.3 to 7.3) | 6.5 (2.7 to 13.0) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical event were included in this outcome measure.
| Percentage of participants | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years |
|---|---|---|
| SSB: Percentage of Participants With SAEs Throughout the Study | 7.3 (3.0 to 14.4) | 14.0 (8.1 to 22.1) |
GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).
| Titer | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years |
|---|---|---|
| RSV A | 2943 (2417.9 to 3580.9) | 3289 (2735.1 to 3954.1) |
| RSV B | 2584 (2120.6 to 3147.9) | 2992 (2416.5 to 3704.1) |
GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).
| Titer | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years |
|---|---|---|
| RSV A | 26173 (19937.1 to 34359.2) | 26075 (20513.1 to 33144.1) |
| RSV B | 24701 (18300.5 to 33340.1) | 25384 (19749.5 to 32626.2) |
GMT of RSV A and RSV B before vaccination were reported in this outcome measure. Assay results below the lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).
| Titer | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years |
|---|---|---|
| RSV A | 21910 (17308.8 to 27733.3) | 25159 (20085.1 to 31515.2) |
| RSV B | 20936 (16154.0 to 27134.4) | 22774 (18016.7 to 28788.3) |
GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).
| Fold rise | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years |
|---|---|---|
| RSV A | 8.8 (6.76 to 11.53) | 7.9 (6.21 to 10.13) |
| RSV B | 9.6 (7.31 to 12.51) | 8.5 (6.70 to 10.75) |
GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).
| Fold rise | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years |
|---|---|---|
| RSV A | 7.4 (5.88 to 9.29) | 7.7 (6.11 to 9.58) |
| RSV B | 8.1 (6.45 to 10.18) | 7.6 (6.06 to 9.57) |
GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).
| Titer | SSA: RSVpreF | SSA: Placebo |
|---|---|---|
| RSV A: Before Vaccination | 2388 (2207.7 to 2583.3) | 2797 (2516.8 to 3108.9) |
| RSV A: 1 month after vaccination | 41595 (38416.6 to 45037.5) | 2660 (2395.2 to 2953.9) |
| RSV B: Before Vaccination | 2075 (1899.7 to 2265.4) | 2230 (1988.6 to 2501.6) |
| RSV B: 1 month after vaccination | 38450 (35187.5 to 42014.7) | 2135 (1905.9 to 2391.3) |
GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).
| Fold rise | SSA: RSVpreF | SSA: Placebo |
|---|---|---|
| RSV A | 17.5 (15.88 to 19.21) | 1.0 (0.90 to 1.00) |
| RSV B | 18.5 (16.76 to 20.43) | 1.0 (0.91 to 1.01) |
Collected over SSA- LR/SE: Within 7Days after Vaccination (Vacc on Day1);AEs: Within 1 Month (M) after Vacc (Vacc on Day1), including any events reported up to 6 months; SAEs: Any events reported up to 6 months; SSB- LR/SE: Within 7 Days after Vacc1 (Day1 of SSB) Within 7 Days after Vacc 2 (second dose on 1M post-vacc.1); AEs: From Vacc 1 (on Day1) through 1M after Vacc 2 (1M after Vacc1) [approximately up to maximum of 2M], including any events reported up to 7 months; SAEs: any events reported up to 7 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SSA: RSVpreF | 1/453 (0.2%) | 5/453 (1.1%) | 301/453 (66.4%) |
| SSA: Placebo | 0/225 (0%) | 7/225 (3.1%) | 135/225 (60%) |
| SSB: RSVpreF, >= 18 to < 60 Years | 0/96 (0%) | 7/96 (7.3%) | 73/96 (76%) |
| SSB: RSVpreF, >= 60 Years | 0/107 (0%) | 15/107 (14%) | 92/107 (86%) |
| Event | SSA: RSVpreF | SSA: Placebo | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years |
|---|---|---|---|---|
| Chest painGeneral disorders | 0/453 | 0/225 | 1/96 | 0/107 |
| Kidney transplant rejectionImmune system disorders | 0/453 | 0/225 | 1/96 | 0/107 |
| COVID-19Infections and infestations | 0/453 | 0/225 | 1/96 | 0/107 |
| CystitisInfections and infestations | 0/453 | 0/225 | 1/96 | 0/107 |
| PneumoniaInfections and infestations | 0/453 | 0/225 | 1/96 | 0/107 |
| UrosepsisInfections and infestations | 0/453 | 0/225 | 1/96 | 0/107 |
| Subdural haematomaInjury, poisoning and procedural complications | 0/453 | 0/225 | 1/96 | 0/107 |
| HypervolaemiaMetabolism and nutrition disorders | 0/453 | 0/225 | 1/96 | 0/107 |
| Deep vein thrombosisVascular disorders | 0/453 | 0/225 | 1/96 | 1/107 |
| HaematomaVascular disorders | 0/453 | 0/225 | 1/96 | 0/107 |
| Event | SSA: RSVpreF | SSA: Placebo | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years |
|---|---|---|---|---|
| Fatigue (FATIGUE)General disorders | 168/453 | 86/225 | 52/96 | 62/107 |
| Injection site pain (PAIN AT INJECTION SITE)General disorders | 159/453 | 24/225 | 54/96 | 41/107 |
| Headache (HEADACHE)Nervous system disorders | 128/453 | 68/225 | 42/96 | 38/107 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 110/453 | 36/225 | 32/96 | 33/107 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 67/453 | 38/225 | 28/96 | 27/107 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 56/453 | 23/225 | 21/96 | 27/107 |
| Nausea (NAUSEA)Gastrointestinal disorders | 53/453 | 23/225 | 15/96 | 13/107 |
| Swelling (SWELLING)General disorders | 32/453 | 2/225 | 9/96 | 12/107 |
| Erythema (REDNESS)Skin and subcutaneous tissue disorders | 27/453 | 1/225 | 7/96 | 8/107 |
| Vomiting (VOMITING)Gastrointestinal disorders | 9/453 | 3/225 | 5/96 | 2/107 |
Safety population included all enrolled participants who received the study intervention.
| Age, Customized(Participants) | SSA: RSVpreF | SSA: Placebo | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years | Total |
|---|---|---|---|---|---|
| 18 to <60 years | 453 | 225 | 96 | 0 | 774 |
| >=60 years | 0 | 0 | 0 | 107 | 107 |
| Sex: Female, Male(Participants) | SSA: RSVpreF | SSA: Placebo | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years | Total |
|---|---|---|---|---|---|
| Female | 260 | 152 | 56 | 53 | 521 |
| Male | 193 | 73 | 40 | 54 | 360 |
| Ethnicity (NIH/OMB)(Participants) | SSA: RSVpreF | SSA: Placebo | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 102 | 48 | 8 | 3 | 161 |
| Not Hispanic or Latino | 348 | 175 | 88 | 101 | 712 |
| Unknown or Not Reported | 3 | 2 | 0 | 3 | 8 |
| Race (NIH/OMB)(Participants) | SSA: RSVpreF | SSA: Placebo | SSB: RSVpreF, >= 18 to < 60 Years | SSB: RSVpreF, >= 60 Years | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 3 | 5 |
| Asian | 24 | 9 | 6 | 2 | 41 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 1 | 0 | 4 |
| Black or African American | 106 | 57 | 25 | 15 | 203 |
| White | 312 | 152 | 63 | 87 | 614 |
| More than one race | 3 | 1 | 0 | 0 | 4 |
| Unknown or Not Reported | 5 | 5 | 0 | 0 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from May 2023 to primary completion in Mar 2024, 10 months.
Results were first posted in Aug 2025, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abrysvo